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Abstract
 Evidence is mounting for the central role of mitochondrial dysfunction in several pathologies including metabolic diseases, 
accelerated ageing, neurodegenerative diseases and in certain xenobiotic-induced organ toxicity. Assessing mitochondrial 
perturbations is not trivial and the outcomes of such investigations are dependent on the cell types used and assays employed. 
Here we systematically investigated the effect of electron transport chain (ETC) inhibitors on multiple mitochondrial-related 
parameters in two human cell types, HepG2 and RPTEC/TERT1. Cells were exposed to a broad range of concentrations of 
20 ETC-inhibiting agrochemicals and capsaicin, consisting of inhibitors of NADH dehydrogenase (Complex I, CI), suc-
cinate dehydrogenase (Complex II, CII) and cytochrome bc1 complex (Complex III, CIII). A battery of tests was utilised, 
including viability assays, lactate production, mitochondrial membrane potential (MMP) and the Seahorse bioanalyser, 
which simultaneously measures extracellular acidification rate [ECAR] and oxygen consumption rate [OCR]. CI inhibitors 
caused a potent decrease in OCR, decreased mitochondrial membrane potential, increased ECAR and increased lactate pro-
duction in both cell types. Twenty-fourhour exposure to CI inhibitors decreased viability of RPTEC/TERT1 cells and 3D 
spheroid-cultured HepG2 cells in the presence of glucose. CI inhibitors decreased 2D HepG2 viability only in the absence 
of glucose. CII inhibitors had no notable effects in intact cells up to 10 µM. CIII inhibitors had similar effects to the CI 
inhibitors. Antimycin A was the most potent CIII inhibitor, with activity in the nanomolar range. The proposed CIII inhibitor 
cyazofamid demonstrated a mitochondrial uncoupling signal in both cell types. The study presents a comprehensive example 
of a mitochondrial assessment workflow and establishes measurable key events of ETC inhibition.
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Introduction
There is accumulating evidence that chemical-induced organ 
toxicity involves disruption of mitochondrial function more 
frequently than previously considered (Dykens and Will 
2007; Will et al. 2019; Dreier et al. 2019). Mitochondrial 
perturbations can have major effects on tissues and organs 
due to their key role in fatty acid metabolism, energy pro-
duction and generation of reactive oxygen species (ROS). 
There are several mechanisms of direct mitochondrial per-
turbation including electron transport chain (ETC) inhibi-
tion, mitochondrial DNA damage, ROS, cardiolipin binding, 
Krebs cycle inhibition, disturbances of fatty acid shuttling, 
beta oxidation inhibition and protonphoretic (uncoupling) 
activity (Boelsterli 2003). The subsequent dysfunction of 
these organelles can have several adverse effects, which is 
both dependent on the target tissue’s reliance on mitochon-
drial function and the type of mitochondrial perturbation.
Various chemical classes may pose human liability for 
mitochondrial toxicity. Several drugs have been withdrawn 
from the market due to organ toxicity, which has subse-
quently been proven or has strong evidence supporting a 
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central role for mitochondrial perturbation (Nadanaciva et al. 
2007; Dykens and Will 2008; Longo et al. 2016; Eakins 
et al. 2016; Grünig et al. 2017). Compounds that fail late in 
clinical trials, or those that are withdrawn from the market 
are costly in terms of financial and time resources, but also 
on patient’s health. The assessment of the potential of drug 
candidates to perturb mitochondria should be a fundamental 
parameter in the early stage of drug development to prevent 
later, often devastating, adverse drug reactions in patients. 
Furthermore, the agrochemical industry has harnessed a 
broad range of effective pesticides and fungicides that act 
via targeting individual complexes of the ETC. Selective 
inhibition of CI and CIII by model mitochondrial toxins has 
been associated with adverse responses in pre-clinical spe-
cies, including neurological defects (Cannon et al. 2009). 
Therefore, a thorough assessment of mitochondrial toxicity 
could also provide important input for risk assessment in 
the case of industrial chemicals and environmental pollut-
ants. While various divergent assays have been established 
to assess mitochondrial perturbations, there is no current 
consensus on the most appropriate assays to use, which com-
binations nor on the most appropriate cell types.
In this study, we aimed to systematically assess the appli-
cability of several assays which could eventually form the 
basis of a consensus mitochondrial toxicity testing platform. 
To this end, we used two human cell lines, the renal RPTEC/
TERT1 and the hepatic HepG2 cells. RPTEC/TERT1 are 
a non-cancerous human telomerase immortalised cell line 
that exhibit a differentiated oxidative phenotype when dif-
ferentiated via contact inhibition (Aschauer et al. 2013). 
The HepG2 cell line under standard 2D conditions exhibit 
a highly proliferative phenotype, but can be further differ-
entiated under 3D spheroid conditions (Ramaiahgari et al. 
2014). We chose a panel of 20 agrochemicals which have 
been harnessed for the selective inhibition of ETC, consist-
ing of inhibitors of NADH dehydrogenase (CI), succinate 
dehydrogenase (CII) and cytochrome bc1 complex (CIII). 
Capsaicin was also included due to its proposed CI activity 
(Satoh et al. 1996). A battery of assays was utilised includ-
ing assays monitoring viability, lactate production, mito-
chondrial membrane potential, and the simultaneous quan-
tification of extracellular acidification and cellular oxygen 
consumption. While this study focuses on ETC inhibition, 
the combination of these assays has the potential to measure 
the majority, if not all, mitochondrial perturbations.
Materials and methods
Chemicals
All tested compounds were purchased from Merck at one site 
(JRC, Ispra, Italy) and distributed to the testing laboratories. 
The catalogue numbers are Capsaicin (Cat. No. M2028), 
Deguelin (D0817), Fenazaquin (31635), Fenpyroximate 
(31684), Pyridaben (46047), Pyrimidifen (35999), Rote-
none (R8875), Tebufenpyrad (46438), Carboxin (45371), 
Fenfuram (45486), Flutolanil (N12004), Mepronil (33361), 
Thifluzamide (49792), Antimycin A (A8674), Azox-
ystrobin (3167), Cyazofamid (33874), Fenamidone (33965), 
Kresoxim-methyl (37899), Picoxystrobin (33568), Pyraclos-
trobin (33696), and Trifloxystrobin (46477). The compounds 
are listed by class in Table 1 and structural information is 
provided in Fig. 1. Stock solutions between 10 and 100 mM 
were created in dimethyl sulfoxide (DMSO) and stored at 
− 20 °C or − 80 °C until use. Treatment solutions were 
prepared freshly from DMSO stocks for each experiment 
and the final concentration of DMSO in the systems was 
0.1% (v/v). For repeated administration, the culture medium 
was removed and the new medium with the compound was 
added every 24 h. 
Cell culture
The human renal proximal tubule-derived cell line RPTEC/
TERT1, is a non-cancerous cell line which was immortalised 
by introduction of the catalytic unit of human telomerase 
(hTERT) (Wieser et al. 2008). These cells were obtained 
under licence from Evercyte GmBH, Vienna Austria. 
RPTEC/TERT1 grow in a monolayer and after reaching 
confluence become contact-inhibited, enter cell cycle arrest 
and differentiate into a transporting epithelium (Aschauer 
et al. 2013). RPTEC/TERT1 at passage numbers between 
72 and 95 were routinely cultured in 10 cm dishes (Sarstedt, 
83.3902) at 37 °C in a 5%  CO2 humidified atmosphere. Cells 
were fed every second to third day with medium contain-
ing 1:1 mixture of Dulbecco’s modified Eagle’s medium 
(DMEM, no glucose, Invitrogen, 11966) and Ham’s F-12 
nutrient mix (Invitrogen, 21765), with a final glucose con-
centration of 5 mM, supplemented with 2 mM glutamax 
(Thermofisher, 350500038), 5 µg/L insulin, 5 µg/L trans-
ferrin and 5 ng/L sodium selenite (Sigma-Aldrich, I1884), 
100 U/mL penicillin and 100 µg/mL streptomycin (Merck, 
P4333), 10 ng/mL epithelial growth factor (Merck, E9644), 
36 ng/mL hydrocortisone (Merck, E9644) and 0.5% foetal 
bovine serum (Gibco, 10720-106). For experiments, cells 
were plated in a required format plate, allowed to become 
contact-inhibited and fed 24 h prior to treatment exposure. 
For experiments in galactose condition, cells were fed 24 h 
prior to experiment with culture medium (custom made 
DMEM/F12, PromoCell) in which 5  mM glucose was 
replaced with 5 mM galactose (Merck, G5388).
The HepG2 cell line, a human hepatocellular carcinoma, 
was obtained from ATCC (American Type Culture Collec-
tion, Wesel, Germany). HepG2 were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM; 25 mM glucose, 
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4 mM l-glutamine, 1 mM sodium pyruvate) (Fisher Scien-
tific, 11504496) supplemented with 10% (v/v) foetal bovine 
serum (Fisher Scientific, S181L-500), 25 U/mL penicillin 
and 25 μg/mL streptomycin (Fisher Scientific, 15070-063). 
Cells were maintained at 37 °C in a 5%  CO2 humidified 
atmosphere, fed every 2 to 3 days and passaged at approxi-
mately 80% confluence. For 2D HepG2 culture, the cells 
plated 48 h before exposures in 384 black µclear plates 
(Greiner Bio-One, 781 091) with a density of 10,000 cells/
well. For galactose experiments, the medium was refreshed 
24 h before exposure with galactose-containing medium. 
Galactose medium consists of glucose-free DMEM (Fisher 
Scientific, 11966-025), 10 mM galactose (Merck, G5388-
100G), 1 mM sodium pyruvate (Sigma, P2256-100 g), 10% 
(v/v) dialysed foetal bovine serum (GE healthcare, 26400-
044), 25 U/mL penicillin and 25 μg/mL streptomycin (Fisher 
Scientific, 15070-063). The protocol for HepG2 3D culture 
was described previously (Ramaiahgari et al. 2014). In short, 
Matrigel™ (BD biosciences, 354230) was diluted with ice-
cold PBS to 5 mg/mL. 10 μL was used to coat a 384-well 
Screenstar plate (Greiner, 781866). Cells were seeded at 
1000 cells per well in DMEM/Hams F12 (Thermo Fisher, 
21041033) supplemented with 10% FBS, 25 U/mL penicillin 
and 25 μg/mL streptomycin. Culture medium was refreshed 
every 3–4 days and the culture was maintained for 21 days 
prior to dosing.
Resazurin assay
The resazurin reduction assay was conducted as previ-
ously described (Jennings et al. 2007). Briefly, an 880 µM 
resazurin stock solution (20×) was generated by dissolv-
ing 0.011 g resazurin (Merck, R7017), in 0.1 N NaOH 
and bringing to 50 mL in phosphate buffer and adjusting 
pH to 7.8. After exposure to compounds, supernatant was 
replaced with 44 µM resazurin stock in cell culture medium 
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III 131860-33-8 403.12 2.50 Fungicide Methoxy-
acrylates




Cyazofamid* III 120116-88-3 324.04 3.20 Fungicide Cyano-imida-
zole
Qi Q-cycle Esser et al. 
(2014)
Fenamidone III 161326-34-7 311.11 3.72 Fungicide Imida-
zolinones




III 143390-89-0 313.13 3.40 Fungicide Oximino-
acetates
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III 175013-18-0 387.10 3.99 Fungicide Methoxy-
carbamates






III 141517-21-7 408.13 4.50 Fungicide Oximino-
acetates




*Refers to the subset of panel compounds in this study. CI (NADH:ubiquinone oxidoreductase), CII (succinate dehydrogenase), CIII 
(cytochrome bc1 complex). ClogP: lipophilicity as reported by Delp et al. (2019). Chemical group from FRAC Code List © 2019. Inhibitor: type 
A—quinone antagonist, type B—semiquinone antagonist, type C—quinol antagonist, Qo—outside quinol oxidation pocket, Qi inside quinone 
reduction pocket, Pf-Qo sub-type I, Pm-Qo sub-type II
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and incubated for 1.5 h to 2 h, at 37 °C in a 5%  CO2 humidi-
fied atmosphere. The conversion of resazurin to fluorescent 
resorufin was measured in a plate reader at excitation/emis-
sion 540/590 nm.
Mitostress assay in intact cells with Seahorse XFe96 
Bioanalyzer
The Seahorse bioanalyzer simultaneously measures cellular 
oxygen consumption rates (OCR) and extracellular acidifica-
tion rates (ECAR). The mitostress assay utilises a sequential 
addition of modulators of the oxidative phosphorylation to 
assess key parameters of mitochondrial function. Subsequent 
injection of oligomycin (Merck, O4876), FCCP (Merck, 
C2920) and a mixture of rotenone (Merck, R8875) and anti-
mycin A (Merck, A8674) provide information on ATP pro-
duction, maximal respiration rates and non-mitochondrial 
respiration, respectively. RPTEC/TERT1 cells were seeded 
onto Seahorse XF96 V3 PS Cell Culture Microplates (Agi-
lent, 101085-004) at the density of 25,000 cells/well and 
allowed to differentiate for a minimum of 2 weeks before 
assay. It is worth noting here that RPTEC/TERT1 require 
longer differentiation time in the Seahorse plates, potentially 
due to sub-optimum gas exchange in the Seahorse culture 
plates. HepG2 cells were cultured at the density of 15,000 
cells/well on collagen-coated (2.5 µg/µL collagen IV, Merck, 
C7521) Seahorse cell culture microplates two days prior to 
analysis.
The mitostress test was performed as described (Eak-
ins et al. 2016; Tilmant et al. 2018). Immediately before 
the assay, cell culture medium was replaced with 180 µL 
of Seahorse XF Base Medium without phenol red (Agi-
lent, 1003335-100), supplemented with 10 mM d-glucose 
(Merck, G7021), 5 mM HEPES (Merck, H4034), 2 mM 
sodium pyruvate (Merck, P5281) and 1 mM l-glutamine 
(Merck, G8540). Cells were allowed to equilibrate for 
Fig. 1  Chemical structures of selected ETC complex I, II, and III 
inhibitors. Molecular structures of all assessed mitochondrial com-
plex inhibitors organised based on their MoA (Table  1). The filled 
orange, purple and green areas highlight the region involved in the 
molecular recognition needed to perform the molecule´s activity for 
CI, CII and CIII inhibitors respectively. The dashed orange circles 
indicate the proposed regions of the pharmacophores for the remain-
ing complex I inhibitors (color figure online)
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45 min in a non-CO2 37 °C incubator. Agilent XFe96 sensor 
cartridge was hydrated 24 h prior to experiments with Sea-
horse XF Calibrant (Agilent, 100840-000) and both placed 
into the Seahorse bioanalyser for assay. Compounds were 
injected sequentially. OCR was measured five times after test 
compound injection and three times for all injections. Each 
measurement consisted of a 3 min mix and subsequent 3 min 
read cycle. The sequence of injection was as follows: (A) test 
compound at 8 concentration points (1 in 5 dilutions starting 
at 10 µM final), (B) oligomycin (2 µM), (C) FCCP (2 µM) 
and (D) rotenone/antimycin A (0.5 µM each). OCR meas-
urement was normalised to the baseline OCR measurement 
prior to compound addition. Measurements were performed 
in triplicate (3 wells) for each independent experiment.
Mitochondrial complex assay with Seahorse XFe96 
Bioanalyser
The mitochondrial complex assay uses real-time OCR 
measurement with sequential addition of specific complex 
substrates and/or inhibitors to identify the complex within 
the ETC that is inhibited. The assay principle explained in 
detail by Salabei et al. (2014) is to sequentially target spe-
cific electron chain complexes. In the first step, cultured cells 
are permeabilised and provided with CI substrates. The test 
compound is injected and OCR is measured. In the second 
step, rotenone and succinate are added which simultaneously 
block CI while suppling substrates to CII. OCR is measured 
for the second time. In the third step, Antimycin A together 
with ascorbate and tetramethyl phenylenediamine (TMPD) 
is added to simultaneously block CIII and supply CIV. A 
third and final OCR measurement is conducted. From the 
patterns of OCR inhibition, one can determine at which part 
of the ETC the compound is exhibiting its effect (Fig. 4).
HepG2 cells were seeded at 20,000 cells/well on Seahorse 
XF96 V3 PS cell culture microplates (Agilent, 101085-004). 
The following day, cells were washed once in mitochondrial 
assay solution (MAS), containing 220 mM mannitol (Sigma, 
M9647), 70 mM sucrose (Sigma, S7903), 10 mM potas-
sium phosphate (Sigma, P5655), 5 mM magnesium chlo-
ride (Sigma, M8266), 3 mM HEPES (Sigma, H0887) and 
1 mM EGTA (Sigma, E4378) with 0.2% fatty acid-free BSA 
(Sigma, A8806). This solution was replaced with 180 µL 
MAS supplemented with 10 mM pyruvate (Sigma, 107360), 
1 mM malate (Sigma, M0875), 4 mM ADP (Sigma, A5285), 
0.2% fatty acid-free bovine serum albumin and 2 nM XF 
plasma membrane permeabilizer (PMP) (Agilent, 102504-
100) and placed immediately into the Seahorse bioanalyser. 
Each measurement consisted of a thirty second mix and two-
minute read cycle. Compounds were injected sequentially 
and OCR was measured twice. The sequence of injection 
was as follows: test compound, succinate (10 mM, Merck, 
S9512) and rotenone (2 µM, Chem Cruz, Sc203242) and 
TMPD (0.5 mM, Merck, T7394), ascorbate (10 mM, Merck, 
A5960) and antimycin A (2 µM, Merck, A8674). Complex 
inhibition was determined using the second OCR measure-
ment after compound/vehicle injection, normalised to the 
baseline OCR measurements prior to compound addition. 
ETC inhibition is determined in decreased OCR. CI inhibi-
tion is confirmed if the inhibited OCR by injection A can 
be rescued after injection B. CII inhibition is determined 
if there is no inhibition after A, but inhibition after B. CIII 
inhibition is determined if there is inhibition after A and 
B, with recovery after C. OCR inhibition after injection C 
indicates effects downstream of CIII.
Mitochondrial membrane potential (MMP) changes 
assays with JC‑1
JC-1 is a single-excitation dual-emission fluorescence-based 
assay that allows for ratiometric semiquantitative assessment 
of mitochondrial membrane potential (Perry et al. 2011). For 
quantification of changes in MMP cells were pre-loaded, 
for approximately 1.5 h, with the JC-1 pre-loading solution 
containing 9 µM JC-1 (Invitrogen, 65-0851-38), 9 µL/mL 
Pluronic F-127 10% in water (Invitrogen, P6866) and 5 µM 
Cyclosporine A (CsA) (Merck, 30024), a P-glycoprotein 
(P-gp) inhibitor, to prevent dye extrusion due to the expres-
sion of efflux pumps in RPTEC/TERT1 cell line. After this 
incubation time, cells were washed and exposed to test com-
pounds dissolved in a JC-1 treatment solution containing 
0.5 µM JC-1, 1.5 µL/mL Pluronic F-127 and 1 µM CsA for 
the desired time. We have previously determined that CsA at 
up to 5 µM has no adverse effect on RPTEC/TERT1 cells for 
up to 14 days (Wilmes et al. 2013). Fluorescence was meas-
ured in a plate reader at excitation 492 nm and dual emis-
sion, 535 nm for monomers and 590 nm for dimers. Results 
are presented as the dimer/monomer ratio and expressed as 
percentage of untreated samples.
Mitochondrial membrane potential plus cell death 
assay using live confocal imaging
Rhodamine 123 (Rho123) (Merck, R8004) was used in a 
live confocal imaging setting for the assessment of effects at 
MMP. Rho123 localises to mitochondria and the decline in 
fluorescence is proportional to a decrease in MMP (Johnson 
et al. 1980, 1981). HepG2 were seeded at 10,000 cells/30 μL/
well in a 384-wells μCLEAR® black plate (Greiner Bio-One, 
781 091). Two days post-seeding, 30 μL complete HepG2 
culture medium, containing 200 ng/μL Hoechst 33342 (Life 
technologies, H1399) and 1 μM Rho123, was added to the 
medium. After 1 h incubation at 37° C, the medium was 
removed and 25 μL complete DMEM containing 0.2 μM 
Rho123 and 100 nM propidium iodide (PI) (Merck, P4170) 
was added, followed by 25 μL of medium containing 2×, 
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the desired concentration of test compound. The intensity of 
Hoechst, Rho123 and PI, was monitored using live confo-
cal imaging for 24 h using the 408, 488 and 561 nm laser, 
respectively. The confocal imaging was performed using 
a Nikon TiE2000 with perfect focus system and xy-stage 
(Nikon, Amsterdam, The Netherlands). Quantification of 
the Hoechst, Rho123 and PI signal intensity and localiza-
tion were performed using CellProfiler version 2.1.1 (Broad 
Institute, Cambridge, USA). The nuclear identification based 
on the Hoechst signal was performed using an internally 
created segmentation module (Di et al. 2012), followed by a 
cytoplasmic identification based on a specific distance from 
these nuclei. The PI-positive nuclei were identified by mask-
ing the previous segmented nuclei and the PI signal. More 
than 10% overlap was considered as PI positive. All CellPro-
filer analyses were stored as HDF5 files. The combination 
of an internally developed R script, run in Rstudio (Boston, 
USA), was used for data extraction including Rho123 signal 
intensity, fraction PI positive and nuclear count.
Lactate assay
The colorimetric assay for the lactate detection is based on 
the conversion of lactate to pyruvate by the lactate dehy-
drogenase (LDH) enzyme. The process is coupled with the 
active reduction of the co-factor NAD to NADH. NADH 
reduces N-methylphenazonium methyl sulfate (PMS) to 
PMSH which reduces p-iodonitrotetrazolium violet (INT) 
to its coloured product INTH (Babson and Phillips 1965) 
detectable in a plate reader. Cells were treated with test com-
pounds for 24 h and at the end of the treatment, superna-
tant medium was collected. Ten microliters of supernatant 
medium was added to 90 μL of reagent mix (80% TRAM 
buffer, 20% colour reagent, 3.3 mM β-NAD (Merck, N7004) 
and 0.33 μL/mL LDH (Merck, L2500)) and incubated in 
light-protected at room temperature for 5 to 10 min. TRAM 
buffer contains 108  mM Triethanolamine HCl (Sigma, 
T9534), 10.7  mM EDTA-Na2 (Merck, E4884), 42  mM 
 MgCl2 (Merck, M8266) in ddH20, pH 7.5. Colour reagent 
contains 1.63 mM PMS (Merck, P9625), 3.95 mM INT 
(Merck, I8377), 35% ethanol, and 2% Triton X-100 (Merck). 
Optical density was measured in a plate reader at 490 nm 
and lactate was quantified against a lactate standard curve 
(Fluka Chemika, 71718) using a spline fit/LOWESS (cubic 
spline) in GraphPad Prism.
Cell death assay in 3D cultured HepG2
At day 21, the culture medium was replaced by fresh 
medium containing the compounds in the desired concen-
tration. During the single exposure scenario, Hoechst (final 
concentration 667 ng/μL) was added to the exposure medium 
and after 24 h the medium was replaced with DMEM/F12 
containing PI (final conc. 400 nM). For the repeat exposure 
scenario, Hoechst was added to the 4th exposure and PI to 
the 5th exposure. Upon 1 h after PI-incubation for the single 
exposure scenario or 24 h after the 5th repeated exposure, 
the Hoechst and PI staining were monitored in 11 z-planes 
using, respectively, the 408 and 561 nm lasers. The confo-
cal imaging was performed using a Nikon TiE2000 with 
perfect focus system and XY-stage (Nikon, Amsterdam, The 
Netherlands). Quantification of the Hoechst and PI signal 
localization was performed using Nis Elements Analysis 
software. First, a max projection was created of all z-stacks. 
The overlapping areas between Hoechst and PI in the pro-
jection picture were assessed based on a manually curated 
intensity threshold. Finally, the fraction of spheroids positive 
for PI staining was determined.
Microarray in HepG2 cells
Transcriptomic data of a previous HepG2 study from the 
de Water lab were used to interrogate potential differences 
in glycolysis gene expression in 3D cultured cells (Hiem-
stra et al. 2019). The study compared 2D at day 3 and 3D 
for 3, 7, 14, 21, and 28 days. The Affymetrix HT Human 
Genome U133 plus platform was used and the original CEL 
files are stored at GEO (Number: GSE128763). Here, we 
pulled out the genes from the Panther glycolysis pathway 
(http://amp.pharm .mssm.edu/Harmo nizom e/gene_set/Glyco 
lysis /PANTH ER+Pathw ays). Values are represented as fold 
changes of HepG2 cells cultured in matrix gel for 3, 7, 14, 21 
or 28 days over HepG2 cells cultured on plastic for 3 days.
Data normalization and statistical analysis
All results are average of 2–3 independent experiments. Each 
independent experiment is referred to as biological replicate 
and includes at least two technical replicates. At first, nor-
malization is applied by representing responses as percent-
age of 0.1% DMSO-treated samples (control) for the follow-
ing assays: resazurin reduction, lactate production, Rho123, 
JC-1, and PI staining. For those assays, a second normaliza-
tion was applied setting as 100% (upper or lower asymptote 
for inhibition or activation curves, respectively), the average 
of at least 2 non-effective concentrations (if applicable), to 
be able to calculate the BMC (Table 2) according to the 
benchmark concentration concept of in vitro toxicology 
(Krebs et al. 2020). For assays performed in Seahorse, basal 
OCR/ECAR responses were normalised as percentage of 
measurements before treatment injection. Maximal OCR 
was normalised as percentage of maximal respiration of con-
trol samples (0.1% DMSO treated). ECAR was normalised 
by setting the lower asymptote of the response curve to 0%, 
corresponding to the 100% ECAR prior to compound injec-
tion (basal acidification), and the upper asymptote to 100%, 
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corresponding to the maximal ECAR induction (oligomy-
cin response). Variation in all performed assays was calcu-
lated and represented as standard deviation (SD). Curves 
were fit using the non-liner regression four-parameter Hill 
model. BMC was calculated using the in vitro toxicology 
on-line tool provided by the group of Prof. Leist, University 
of Konstanz (Krebs et al. 2020). Significance levels were 
calculated comparing treatment responses to assay´s specific 
control using one way ANOVA followed by a Dunnett’s test, 
*p < 0.05 (Tables 3, 4). Data analysis was performed using 
Rstudio (Boston, USA) R 3.6.0 and included the follow-
ing packages dply (Wickham 2011), tidyr (Wickham 2016), 
data.table (Dowle et al. 2016), multcomp (Hothorn et al. 
2008) and stats.
Results
Effects of various selective ETC‑complex inhibitors 
on viability and OCR
In both cell lines, mitochondrial and metabolic param-
eters were measured upon exposure to a broad concentra-
tion range of in total 21 mitochondrial ETC CI, CII and 
CIII inhibitors. The capacity of cells to reduce resazurin is 
widely used as a viability assay due to its ease of use and low 
cost (Jennings et al. 2004, 2007). Resazurin reduction was 
measured in both cell types after 24 h exposure of test com-
pounds at a range of concentrations up to 10 µM. Cell via-
bility decreased in a concentration-dependent manner upon 
exposure to 15 out of 21 complex inhibitors in the RPTEC/
TERT1 cell line, whereas only rotenone mildly affected the 
viability of HepG2 cells (Fig. 2). The CII inhibitors and 
(A)
(B)
Fig. 2  Effect of compound exposure on cellular viability as measured 
by resazurin reduction. a Schematic representation of the experimen-
tal setup in RPTEC/TERT1 and HepG2 cells, the red line represents 
the exposure time. b Concentration response curves of resazurin 
reduction in RPTEC/TERT1 and HepG2 cells exposed for 24 h to a 
range of concentrations (1.28E−10, 6.40E−10, 3.20E−9, 1.60E−8, 
8.00E−8, 4.00E−7, 2.00E−6, 1.00E−5M) of complex I, complex 
II and complex III inhibitors of the ETC. RPTEC/TERT1 (red) and 
HepG2 (blue). Values are represented as percentage of vehicle con-
trols (0.1% DMSO) and further normalized to the average of at least 
two non-effective concentrations (if applicable) set as 100%. Meas-
urements are average of at least three independent experiments ± SD. 
Connecting lines are non-linear fits (Y = bottom + (top  −  bottom)/
(1 + 10^((LogIC50-X) × HillSlope))) (color figure online)
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capsaicin did not affect resazurin reduction up to 10 µM in 
a 24 h exposure.
Mitochondrial oxygen consumption rate (OCR) was 
quantified in intact RPTEC/TERT1 and HepG2 cells using 
the Seahorse XFe96 Bioanalyzer (Agilent). OCR was quanti-
fied for 30 min immediately after test compound injection to 
estimate the effect of compound on basal respiration. After 
30 min, oligomycin was injected to estimate mitochondrial 
ATP production. Thereafter, FCCP was injected to provide 
maximal mitochondrial respiration. Finally, rotenone and 
antimycin A were injected to assess non-mitochondrial res-
piration (Fig. 3). Comparison of untreated cells revealed a 
2.2-fold higher maximal respiration rates in RPTEC/TERT1 
cells compared to HepG2 cells (RPTEC/TERT1 337.4% 
basal OCR ± 72.9, HepG2 159.4% basal OCR ± 26.8) 
(Fig. 3b).
CI inhibitors, except for capsaicin, induced a concen-
tration-dependent decrease in basal and maximal OCR in 
both cell lines (Fig. 3d, e). The effects were comparable 
in both cell types with pyrimidifen being the most potent 
of the entire CI class. None of the CII inhibitors exhibited 
an effect in basal OCR. However, some of the compounds, 
including thifluzamide, showed a tendency to increase maxi-
mal respiration at higher concentrations in RPTEC/TERT1 
cells (Fig. 3d, e). CIII inhibitors exhibited a dose-dependent 
decrease in basal and maximal OCR, in both cell types with 
the exception of cyazofamid (Fig. 3d, e). Antimycin A was 
the most potent of the CIII class. Cyazofamid demonstrated 
a strong uncoupling effect, with a more pronounced effect 
in RPTEC/TERT1 cells (Fig. 3d). Note that the Y-axis in 
Fig. 3d is extended to 300% due to this effect, where all other 
graphs have a scale from 0 to 180%. The Seahorse mitostress 
OCR plots for cyazofamid are provided in Fig. 3f, which 
more clearly shows the uncoupling effect at 2 and 10 µM in 
both cell types.
Mitochondrial ETC‑complex inhibition specificity
To confirm the specificity of the various ETC inhibitors and 
to rule out confounding pharmacokinetic effects, such as 
lack of transport or metabolism, Seahorse measurements 
were conducted in permeabilised HepG2 cells with sequen-
tial addition of paired ETC-complex substrates and inhibi-
tors (Fig. 4). All CI inhibitors including capsaicin (50 µM 
and above) exhibited the expected CI-specificity pattern, i.e. 
inhibition of OCR after injection and recovery with succi-
nate. All CII inhibitors exhibited CII-specificity pattern, i.e. 
no (or less potent) OCR inhibition after direct injection but 
OCR inhibition after succinate/rotenone injection. However, 
only carboxin and thifluzamide exhibited activity at or below 
10 µM. CIII inhibition is determined by OCR inhibition after 
compound injection, no recovery with succinate, but recov-
ery with ascorbate/TMPD. Antimycin A, kresoxim-methyl, 
picoxystrobin, pyraclostrobin and trifloxystrobin conformed 
to this pattern, while azoxystrobin and fenamidone were only 
partially rescued with ascorbate/TMPD. Cyazofamid exhib-
ited a CII inhibition pattern but only at 100 µM.
Monitoring mitochondrial membrane potential 
(MMP)
Live cell imaging was used to measure MMP in HepG2 uti-
lising Rho123, whereas JC-1 dimer/monomer ratio meas-
ured with a plate reader was used to assess changes in MMP 
in RPTEC/TERT1 cells. For reasons, we did not elucidate 
Rho123 as it was unresponsive in RPTEC/TERT1 cells and, 
hence, the JC-1 dye was used. A decrease in Rho123 inten-
sity is representative for reduced MMP, while JC-1 red/green 
ratio shifts to the green with decreasing MMP (Fig. 5a). 
MMP decreased in a concentration-dependent manner 
in both cell types with CI inhibitors, except for capsaicin 
(Fig. 5b). CII inhibitors did not decrease MMP in RPTEC/
TERT1 cells; flutolanil and mepronil actually increased it. In 
HepG2 cells, flutolanil, mepronil and thifluzamide decreased 
MMP, but only at the highest concentrations. Exposure to 
Table 3  Statistical significance of concentration responses relative to all performed experiments excluding ETC inhibition specificity assay
Viability Viability
Glucose settings Galactose settings
Compound Complex Resazurin Resazurin PI staining PI staining
RPTEC/TERT1 HepG2 RPTEC/TERT1 HepG2 HepG2 3D HepG2 3D RPTEC/TERT1 HepG2 RPTEC/TERT1 HepG2 RPTEC/TERT1 HepG2 RPTEC/TERT1 HepG2 RPTEC/TERT1 HepG2
a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h a b c d e f g h
Capsaicin CI * * * * * *
Deguelin CI * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Fenazaquin CI * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Fenpyroximate CI * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Pyridaben CI * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Pyrimidifen CI * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Rotenone CI * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Tebufenpyrad CI * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Carboxine CII * * * * * *
Fenfuram CII * * * * * * * *
Fluto lanil CII * * * * * *
M epronil CII * * * * * * *
Thifluzamide CII * * * *
Antimycin A CIII * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Azoxystrobin CIII * * * * * * * * * * * * * * * * * * * * *
Cyazofamid CIII * * * * * * * * * * * * * * * *
Fenamidone CIII * * * * * * * * * * * * * * * * *
Kresoxim-methyl CIII * * * * * * *
Picoxystrobin CIII * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Pyraclostrobin CIII * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *





(1x 24h) M M P Lactate production ECAR basal OCR basal
Significance levels were calculated comparing treatment responses to assay´s specific control using one way ANOVA followed by a Dunnett’s 
test, *p < 0.05. Light grey = chemical not tested in particular assay, dark grey = not enough replicates to perform statistics. The numbers corre-
spond to the used concentrations in µM: a = 0.000128, b = 0.0064, c = 0.0032, d = 0.016, e = 0.08, f = 0.4, g = 7 and h = 10
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all CIII inhibitors, except for kresoxim-methyl and triflox-
ystrobin, led to decreased MMP in both cell systems.
Increased glycolysis by inhibitors of CI and CIII
Exposure to CI and CIII inhibitors for 24 h resulted in an 
increase in supernatant lactate in both cell types, with the 
exception of capsaicin and kresoxim-methyl. No effect was 
observed when exposing cells to CII inhibitors at tested con-
centrations (Fig. 6a). Overall, RPTEC/TERT1 cells showed 
a more pronounced increased glycolysis compared to HepG2 
cells. Utilising the Seahorse measurement of ECAR, after 
direct injection of compounds, a rapid increase in response 
to CI and CIII inhibitors was observed, with no increase 
in ECAR for CII inhibitors (Fig. 6b–d). Similar ECAR 
responses were observed in both cell systems, although 
cyazofamid was much more potent in RPTEC/TERT1 
cells. Both cell types showed a robust increase in ECAR 
in response to oligomycin; however, only RPTEC/TERT1 
further increased ECAR in response to FCCP (Fig. 6c).
Glu/Gal switch sensitises towards ETC 
inhibition‑induced toxicity in HepG2 cells 
but not RPTEC/TERT1 cells
We evaluated the effect of glucose removal on the sensitiv-
ity of RPTEC/TERT1 and HepG2 cells to a restricted com-
pound panel of CI and CIII inhibitors (Fig. 7). Cells were 
switched from glucose to galactose containing medium one 
day before chemical exposure (Fig. 7). Cell viability was 
measured after 24 h exposure to a subset of compounds. 
Replacing glucose with galactose had no clear effect on 
the viability to chemical exposure in RPTEC/TERT1 cells 
(Fig. 7). In contrast, galactose conditions strongly sensitised 
Table 4  Statistical significance of concentration responses relative to MRC complex inhibition specificity assay
a b c d e f g h i j k l m n o p q r s t a b c d e f g h i j k l m n o p q r s t a b c d e f g h i j k l m n o p q r s t
Capsaicin CI * *
Deguelin CI * * * * * *
Fenazaquin CI * * * * * * * * *
Fenpyroximate CI * * * *
Pyridaben CI * * * *
Pyrimidifen CI * * * * *
Rotenone CI * * * * *
Tebufenpyrad CI * * * *
Carboxine CII * * * * *
Fenfuram CII * * *
Fluto lanil CII * * * * * * * * * * * *
M epronil CII * * * *
Thifluzamide CII * * * * * *
Antimycin A CIII * * * * * * * * * *
Azoxystrobin CIII * * * * * * *
Cyazofamid CIII
Fenamidone CIII
Kresoxim-methyl CIII * * * * * * * * * *
Picoxystrobin CIII * * * * * * * *
Pyraclostrobin CIII * * * * * *
Trifloxystrobin CIII * * * * * * * *
Compound Complex
OCR basal - Permeabilised cells
M easurement 1 M easurement 2 M easurement 3
Significance levels were calculated comparing responses to assay controls using one way ANOVA followed by a Dunnett’s test, *p < 0.05. Light 
grey = chemical not tested in particular assay. The numbers correspond to the used concentrations in µM: a = 0.00001, b = 0.0001, c = 0.001, 
d = 0.00316, e = 0.01, f = 0.316, g = 0.1, h = 0.316, i = 0.5, j = 1, k = 1.58, l = 3.16, m = 5, n = 10, o = 15.8, p = 31.6, q = 50, r = 100, s = 158 and 
t = 500
Fig. 3  Oxygen consumption rates in untreated and treated RPTEC/
TERT1 and HepG2 cells. Effect on key parameters of mitochon-
drial function measured as changes in OCR with the Seahorse ana-
lyser upon 30  min exposure to range of concentrations (1.28E−10, 
6.40E−10, 3.20E−9, 1.60E−8, 8.00E−8, 4.00E−7, 2.00E−6, 
1.00E−5M) of complex I, complex II and complex III inhibitors of 
the ETC in RPTEC/TERT1 and HepG2 cells. a Overview of meas-
urable parameters after subsequent injections of test compound and 
modulators of the oxidative phosphorylation of the mitostress assay 
in HepG2 cells. Respiration is first measured at the basal level of test 
system (I). Decrease in OCR upon test compound injection, indicate 
inhibition of the mitochondrial respiration (II). Changes in OCR 
upon oligomycin addition, indicate the portion of oxygen employed 
in ATP production (III). OCR increases after the protonophore addi-
tion indicates the maximal ability of the cell to increase mitochon-
drial respiration (IV). Addition of antimycin A and rotenone allows 
for identification of non-mitochondrial respiration (V). The differ-
ence between oligomycin and rotenone/antimycin response indicates 
the remaining basal respiration not coupled with ATP production to 
be attributed to proton leakage (VI). Arrows indicate time of injec-
tions. b OCR changes after mitostress test conducted in 0.1% DMSO 
control samples in RPTEC/TERT1 and HepG2. Data are represented 
as mean of at least seven independent experiments, expressed as per-
centage of basal respiration ± SD. c Representative response upon 
exposure to rotenone (1.28E−10, 6.40E−10, 3.20E−9, 1.60E−8, 
8.00E−8, 4.00E−7, 2.00E−6, 1.00E−5M) in HepG2 cells showing a 
dose dependent effect in basal (I) and maximal (II) respiration rates. 
d, e Plots of concentration responses in terms of oxygen consumption 
rates extrapolated from the mitostress test of panel compounds. Data 
represents the mean of two independent experiments ± SD. All meas-
urements were normalized for basal respiration prior to compound 
injection, slopes are generated by plotting dose responses of the direct 
oxygen consumption inhibition (OCR basal, D) and inhibition of the 
uncoupler stimulated respiration (OCR maximal respiration, E), the 
latter further represented as percentage of untreated controls samples. 
f Response of the mitostress assay after treatment with different con-
centrations of cyazofamid (1.28E−10, 6.40E−10, 3.20E−9, 1.60E−8, 
8.00E−8, 4.00E−7, 2.00E−6, 1.00E−5M). The two highest concen-
trations indicate the uncoupling effect of the compound in the two 
cell systems
◂
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HepG2 cells to the OCR active compounds, underlining the 
dependency of HepG2 cells on glycolysis under mitotoxi-
cant-induced stress conditions and making this system more 
comparable to the RPTEC/TERT1 cells (Fig. 7).
Effect of 3D spheroid culture and repeated 
exposures in HepG2 cells
There is evidence to suggest that HepG2 cells cultured in 
3D spheroids results in decreased proliferation and reduced 
reliance on glucose (Hiemstra et al. 2019). Thus, we inves-
tigated if HepG2 3D spheroids had an increased sensitiv-
ity to the ETC inhibitors. We compared the effect of 24 h 
exposure to a range of concentrations of a set of CI, CII and 
CIII inhibitors in HepG2 monolayer and HepG2 spheroids 
(Fig. 8d). The combination of the cellular nuclear staining 
(Hoechst) and the cell death staining (PI) showed a sub-
stantial increase in cell death in HepG2 spheroids-treated 
samples (Fig. 8d, blue curve) when compared to HepG2 
monolayer-treated cells (Fig. 8d, orange curve). This effect 
was more prominent in most of the CI inhibitor-treated sam-
ples and antimycin A. In contrast, only visible for the highest 
concentration of pyraclostrobin was seen in the remaining 
CIII inhibitor-treated samples. Capsaicin and CII inhibition 
did not show increased sensitivity in spheroids compared to 
the 2D model.
Since 3D HepG2 can also be utilised over longer expo-
sure periods, we investigated the effect of a 5 day repeated 
24 h exposure (5 × 24 h) compared to the 24 h bolus expo-
sure (1 × 24 h). The 5 × 24 h exposure, increased sensitiv-
ity to rotenone (EC50 127 nM 1 × 24 h, 28 nM 5 × 24 h) 
and antimycin A (EC50 > 10 µM 1 × 2 4 h, 74 nM 5 × 24 h) 
(Fig. 8d, Table 2).
Correlation plots
To give an overview of the data and to explore the rela-
tionship between OCR/ECAR and the viability, lactate and 
MMP assays, correlation plots of all the data were generated 
(Fig. 9). Matched data for 24 h resazurin reduction, 24 h 
MMP, 24 h supernatant lactate concentration and 30 min 
ECAR are plotted vs basal 30 min OCR data (Fig. 9). In 
addition, 24 h lactate production is plotted vs 30 min basal 
ECAR (Fig. 9). In RPTEC/TERT1 cells, acute basal OCR 
correlated with 24 h viability, as measured by resazurin 
reduction (Fig. 9a, b) (glucose conditions r2 = 0.7723, galac-
tose conditions r2 = 0.8081), with 24 h MMP, as measured by 
JC-1 ratio (Fig. 9c) (r2 = 0.6495), with acute ECAR (Fig. 9d) 
(negative correlation, r2 = 0.8369) and with 24 h supernatant 
lactate (Fig. 9e) (negative correlation, r2 = 0.8083). Super-
natant 24 h lactate correlated with acute ECAR (Fig. 9f) 
(r2 = 0.7339). In HepG2 cells, there was a poor correla-
tion of acute basal OCR with 24 h viability under glucose 
conditions (Fig. 9a) (r2 = 0.4047). However, this improved 
under galactose conditions (Fig. 9b) (r2 = 0.8217). Acute 
basal OCR correlated with MMP, as measured by Rho-123 
(Fig. 9c) (r2 = 0.6661), with acute basal ECAR (Fig. 9d) 
(negative correlation, r2 = 0.8867) and with 24 h superna-
tant lactate (Fig. 9d) (negative correlation, r2 = 0.6395). 
Supernatant lactate correlated with acute ECAR (Fig. 9c) 
(r2 = 0.649), although the distribution range is smaller than 
in RPTEC/TERT1 cells.
Discussion
 We have assessed a panel of proposed ETC inhibitors in 
two human cell lines, with several assays and in various 
different modes to provide a basis for the establishment of a 
(F)
Fig. 3  (continued)





Fig. 4  Identification of ETC target using the mitochondrial complex 
assay. a Schematic representation of the ETC complex inhibition 
assay. The complex inhibition assay consists of a sequential injection 
(in the same well) of substrates and/or inhibitors to determine spe-
cific complex inhibition. Initially cells are treated with permeabiliz-
ing agent and CI substrates (pyruvate/malate/ADP) (Step 1). Cells are 
subsequently injected with test chemical, followed by a second injec-
tion with CII substrate (succinate) and CI inhibitor (rotenone) simul-
taneously (Step 2), and finally a complex IV substrate (ascorbate/
TMPD) and CIII inhibitor (antimycin A) is added (Step 3), followed 
by ORC measurement. b Schematic representation of expected OCR 
responses upon test compound and sequential assay substrates and/or 
inhibitors addition. Following test chemical injection, OCR is meas-
ured (measurement 1, grey line). Decreased OCR indicates an inhi-
bition of the ETC (unknown complex), no effect on OCR indicates 
either inhibition of CII, case 3 (established in the next assay measure-
ments) or no ETC inhibition (case 1). Addition of rotenone and suc-
cinate at step 2, blocks CI and drives CII respectively. OCR is meas-
ured after step 2 (measurement 2, purple line). A rescue in decreased 
OCR indicates the test compound as CI inhibitor (case 2), a continua-
tion in the drop of OCR indicates the site of inhibition is downstream 
of CI and a decrease in OCR where not observed previously indicates 
CII inhibition (case 3). Addition of antimycin A and ascorbate/TMPD 
at step 3, blocks CIII and drives CIV respectively. OCR is measured 
after step 3 (measurement 3, orange line). A rescue in decreased OCR 
indicates the test compound as CIII inhibitor (case 4) or confirms the 
test compound as CII inhibitor (case 3), a continuation in the drop of 
OCR indicates CIV or CV as the site of inhibition (case 5). c Plots of 
dose responses in OCR for panel compounds in HepG2 cells. OCR 
is expressed as percentage of baseline response prior to compound 
exposure, data is mean of 3 independent experiments ± SD. A drop 
in measurement 1 OCR (grey line) alone indicates inhibition of com-
plex I, drop in measurement 2 OCR (purple line) alone indicates CII 
inhibition and drop in measurement 1 and measurement 2 together 
indicates CIII inhibition. A drop in measurement 3 OCR (orange line) 
indicates CIV or CV inhibition and/or off target effects (color figure 
online)
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comprehensive workflow for assessing the impact of chemi-
cals on mitochondrial function and the cellular consequences 
thereof.
Given the central role of mitochondria in energy metabo-
lism, tissue health and ageing, there is increasing concern 
regarding the long-term effect that xenobiotics may have 
on mitochondrial function. Mitochondrial perturbations are 
likely to increase sensitivity to xenobiotics, decrease cel-
lular repair mechanisms and contribute to both chronic dis-
ease states and accelerated ageing (Will et al. 2019). The 
most direct method to assess mitochondrial activity is by 
measuring oxygen consumption rates (OCR). Situations that 
(A)
(B)
Fig. 5  Effect of compound exposure on mitochondrial membrane 
potential. Effect on mitochondrial membrane polarization by assess-
ment of changes in mitochondrial membrane potential upon 24  h 
exposure to range of concentrations (1.28E−10, 6.40E−10, 3.20E−9, 
1.60E−8, 8.00E−8, 4.00E−7, 2.00E−6, 1.00E−5M) of complex I, 
complex II and complex III inhibitors of the ETC in RPTEC/TERT1 
and HepG2 cells. a Schematic representation of mitochondrial mem-
brane depolarization using JC-1 and Rho123 in RPTEC/TERT1 
and HepG2 respectively and representative images of changes in 
mitochondrial membrane polarization in RPTEC/TERT (JC-1) and 
HepG2 (Rho123) upon exposure to vehicle control, rotenone and 
antimycin A. b Concentration response curves of panel compounds 
in RPTEC/TERT1 (red) and HepG2 (blue). The Rho123 intensity 
and the intensity ratio for JC-1 were presented as percentage of 0.1% 
DMSO exposure. The data was further normalized to the average of 
at least two non-effective concentrations (if applicable). Measure-
ments are expressed as average of at least three independent experi-
ments ± SD (color figure online)
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impair mitochondrial function can lead to a decrease in cell 
viability, but usually there is first an increase in glycolytic 
rates. Altered glycolytic status can be quantified by assessing 
extracellular acidification rates (ECAR), or biochemically 
by measuring supernatant lactate (Limonciel et al. 2011). 
The Seahorse bioanalyser coupled with the mitostress assay 
is becoming an industry standard for the quantification of 
OCR and ECAR (Divakaruni et al. 2014; Eakins et al. 2016; 
Tilmant et al. 2018). Other methods to assess mitochondrial 
function include live cell dyes, which under optimised con-
ditions can be related to MMP or comparing toxicity in the 
presence and absence of glucose as an energy source.
Respiration rates were similarly affected in both RPTEC/
TERT1 and HepG2 cells exposed for 30 min to the 21 com-
pounds. In sharp contrast, the effect of ETC inhibition on 
cell viability after 24 h exposure was cell type- and test 
system-dependent. Differentiated RPTEC/TERT1 cell via-
bility correlated with OCR inhibition independently of the 
presence of glucose. HepG2 cell viability correlated with 
OCR inhibition only in the absence of glucose. Interest-
ingly, culturing HepG2 as 3D spheroids sensitised the cells 
to OCR inhibition in the presence of glucose. Previous stud-
ies have demonstrated that 3D spheroid culture of HepG2 
cells decreases proliferation, increases differentiation and 
increases sensitivity to various compounds with human 
drug-induced liver injury liability (Ramaiahgari et al. 2014; 
Hiemstra et al. 2019). Taken together, the data suggest that 
proliferating cells are less reliant on oxidative phosphoryla-
tion as an energy source where glucose is not limiting and 
that 3D HepG2 cells switch towards an oxidative phospho-
rylation-mediated energy source.
With the exception of capsaicin, all of the CI inhibitors 
acutely reduced OCR and enhanced ECAR. In the mito-
chondrial complex assay, decreased OCR could be rescued 
with the addition of succinate confirming CI as the site of 
inhibition for these compounds. Pyrimidifen, deguelin and 
rotenone were the most potent CI compounds with IC50s in 
the nanomolar range. Capsaicin was also confirmed as a CI 
inhibitor, albeit with lower potency (LOEL 50 µM and IC50 
approximately 260 µM).
CII inhibitors did not alter cell viability, basal OCR, 
ECAR or lactate production in living, non-permeabilised 
cells at concentrations up to 10 µM. However, in the permea-
bilised assay, all compounds were confirmed as CII specific, 
albeit at concentrations, close to or above, the maximum 
concentration tested in intact cells. This difference can be 
attributed to the fact that CII activity is less critical for elec-
tron transfer and ATP production than CI and CIII and is 
neither required for CI to CIII electron transfer, nor does it 
participate in proton pumping. CII gives a minor contribu-
tion to the Q-cycle compared to CI and, therefore, its inhi-
bition can be totally (thifluzamide) or partially (carboxin, 
fenfuram, flutolanil and mepronil) masked from CI activity, 
depending on the strength of the CII inhibition. Indeed, it 
has been demonstrated that CII activity is more important 
for ATP generation where energy demand is high (Pfleger 
et al. 2015) or when CI substrates are limiting (Salabei et al. 
2014). However, since CII is directly coupled to the Kreb’s 
cycle, it would be expected that CII inhibition would even-
tually negatively impact OCR due to NADH and  FADH2 
depletion, affecting CI and CII activity, respectively. Also, 
under our experimental settings, pyruvate was present, 
which may be enough to supply the Krebs cycle until the 
succinate oxidation step, thus, limiting depletion of NADH. 
Flutolanil and mepronil do appear to slightly increase MMP 
in RPTEC/TERT1 cells, although this was not significant. 
There was also a non-significant tendency of CII compounds 
to increase maximal OCR in RPTEC/TERT1 cells. These 
effects are possibly a compensatory mechanism of CII inhi-
bition leading to inner mitochondrial hyperpolarisation. 
However, further investigations would need to be conducted 
to address this possible mechanism specifically.
The mitochondrial complex assay confirmed CIII as the 
site of inhibition of 5 of the 8 compounds previously classified 
as CIII inhibitors. Contrary to how the system senses the elec-
tron flow from CII, CIII inhibition results in the total block 
of the Q-cycle as it receives electrons from both CI and CII; 
therefore, concomitant inhibition of CI and succinate addi-
tion does not further decrease OCR when CIII inhibitors are 
applied. Azoxystrobin and fenamidone were only partially res-
cued by ascorbate/TMPD, which may indicate off-target activ-
ity at CIV/CV or some other non-specific activity. Antimycin 
A was the most potent CIII inhibitor, with IC50s for most 
parameters in the nanomolar range. Since CIII receives elec-
trons from both CI and CII, complete CIII inhibition would 
be expected to have a major impact, as it is the case for anti-
mycin A. It appears we did not achieve full CIII inhibition for 
azoxystrobin, fenamidone, trifloxystrobin or kresoxim-methyl 
as OCR inhibition did not reach 100%. Surprisingly, cyazo-
famid did not inhibit OCR, on the contrary, it was the only 
test compound that demonstrated potent uncoupling effects, 
evidenced by an increase in basal OCR in the mitostress assay. 
Thus, under our assay settings, cyazofamid is a potent mito-
chondrial uncoupler and is, therefore, unlikely to be a classical 
CIII inhibitor as previously described (Li et al. 2014). While 
cyazofamid is small and lipophilic, it does not conform to 
the primary characteristic of classical protonophoretic com-
pounds, such as FCCP and PCP, which are weak acids. This 
feature is necessary to facilitate the transfer a hydrogen from 
the inner membrane space to the mitochondrial matrix (Benz 
and McLaughlin 1983). Thus, the protonophoretic effect of 
cyazofamid is potentially atypical and requires further atten-
tion to identify whether CIII is involved.
Risk assessment is intrinsically linked to exposure 
duration and frequency of the exposure. To assess the 
effects of repeated exposures to ETC inhibitors including 
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possible sensitisation towards cellular toxicity, we exposed 
3D HepG2 spheroids for 5 consecutive days to 24 h admin-
istration to a selection of 14 of the ETC inhibitors and 
compared the results to a one time 24 h exposure. Repeated 
exposure increased the toxic sensitivity for rotenone, 
tebufenpyrad, antimycin A, picoxystrobin and pyraclos-
trobin, but not to the other compounds tested. However, the 
increased sensitivity was minimal and does not fully justify 
the extra effort involved. This may be explained by the fact 
this set of compounds are very fast acting (within 5 min) 
and are, thus, unlikely to have accumulative effects of ETC 
inhibition upon sequential exposures. Also, it is possible that 
unless there is a major inhibition of the ETC, compensa-
tory mechanisms, such as increased glucose utilisation, can 
cover the energy deficit. We caution that this should not be 
assumed for other chemicals, in particular when mitochon-
drial toxicity is caused through indirect mechanisms, such 
as inhibition of mitochondrial DNA replication (Dykens and 
Will 2007; Nadanaciva et al. 2007).
A major current emphasis in transitioning mode of 
action toxicology to risk-assessment regimes is the focus 
on adverse outcome pathways, including identification of 
molecular initiating events (MIE) and key events (KE), lead-
ing to a particular pathology (Leist et al. 2017). The cur-
rent data support a generic AOP framework for mitochon-
drial ETC inhibition, where CI and CIII inhibition directly 
leads to a decreased mitochondrial respiration. This leads 
almost immediately to an increase in glycolysis, which can 
Fig. 6  Effect of compound exposure on extracellular lactate and 
extracellular acidification rates. Glycolytic switch upon decreased 
mitochondrial respiration was indirectly assessed by measurements 
of supernatant lactate and the extracellular medium acidification 
after 24 h exposure to range of concentrations (1.28E−10, 6.40E−10, 
3.20E−9, 1.60E−8, 8.00E−8, 4.00E−7, 2.00E−6, 1.00E−5M) 
of complex I, complex II and complex III inhibitors of the ETC in 
RPTEC/TERT1 and HepG2 cells. a Levels of lactate in the super-
natant medium. Data are represented as percentage of 0.1% DMSO 
controls and re-normalized to the average of at least two non-effective 
concentrations (if applicable) set as 100%. b Representative response 
to the testing concentration range of rotenone in HepG2 cells show-
ing a dose dependent increase of medium acidification (I) reflecting 
the glycolytic turnover increase. c Changes in ECAR after mitostress 
test conducted in 0.1% DMSO control samples in RPTEC/TERT1 
and HepG2. Data are represented as mean of at least seven independ-
ent experiments, expressed as percentage of basal acidification ± SD. 
d Plots of concentration responses of changes in ECAR after panel 
compounds injection. Data is mean of two independent experi-
ments ± SD. Measurements are expressed as percentage of basal 
acidification and further normalized by setting the lower asymptote 
of the response curve to 0%, corresponding to the 100% ECAR prior 
to compound injection (basal acidification), and the upper asymptote 





Fig. 7  Effect of medium glucose on compound induced alterations 
in cell viability. The effects of medium switch (glucose to galac-
tose) in terms of cell viability was assessed in RPTEC/TERT1 and in 
HepG2 after 24 h exposure to a range of concentrations (1.28E−10, 
6.40E−10, 3.20E−9, 1.60E−8, 8.00E−8, 4.00E−7, 2.00E−6, 
1.00E−5M) of complex I, complex II and complex III inhibitors of 
the ETC. a Schematic representation of the carbon source switch 
from glucose to galactose-containing medium in RPTEC/TERT1 
(5 mM Glu/Gal) and HepG2 (25 mM Glu/Gal) respectively, the red 
line represents the exposure time. b Plots of concentration responses 
in resazurin reduction. Measurements are expressed as percentage of 
vehicle controls (0.1% DMSO) and further normalized to the aver-
age of at least two non-effective concentrations (if applicable) set as 
100%. Values are mean of two to four independent experiments ± SD. 
Connecting lines are non-linear fits (Y = bottom + (top  −  bottom)/
(1 + 10^((LogIC50-X) × HillSlope)))
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accomplish energetic needs in cells less reliant on oxidative 
phosphorylation and where glucose is not limiting. Thus, 
CI or CIII inhibition is the MIE and decreased OCR is the 
initial KE and increased ECAR and/or increased supernatant 
lactate is the second KE. Decrease in MMP might be indica-





Fig. 8  Comparison of compound induced toxicity in 2D cultured 
HepG2 and 3D HepG2 spheroids. a Schematic representation of cell 
culture/differentiation protocol and time of endpoint measurements 
in HepG2 spheroids treated with two exposure regimes; I = 1 × 24 h 
exposure, measured after 24 h and II = 5 × 24 h exposure, measured 
after 120 h. b (I) Schematic representation of HepG2 spheroids in a 
384 well, with a representative picture of a single spheroid stained 
with nuclear marker (Hoechst) and cell death marker (PI). (II) Rep-
resentative images of a 384 well with spheroids cultured in glucose-
containing medium followed by exposure to 10  µM rotenone or 
DMSO (24 h) and stained with nuclear marker and cell death marker. 
c Heatmap of changes in glycolytic enzyme genes during HepG2 
spheroids maturation, in medium containing glucose, showing the 
evolution toward a less glycolytic state. Log2 fold changes represent 
the expression of untreated HepG2 cells cultured in matrix gel (3D) 
at day 3, 7, 14 (proliferating cells) and 21, 28 (non-proliferating sphe-
roids) over untreated HepG2 cells cultured on plastic (2D) for 3 days. 
d Difference in the cytotoxicity responses upon treatment with a 
range of concentrations (1.28E−10, 6.40E−10, 3.20E−9, 1.60E−8, 
8.00E−8, 4.00E−7, 2.00E−6, 1.00E−5M) of CI, CII and CIII inhibi-
tors in HepG2 monolayer (2D) and HepG2 spheroids  (3D) with a 1 
x 24 h exposure or a consecutive 5 × 24 h exposure. All conditions 
are in glucose containing medium. Cell death endpoint was assessed 
with PI staining at the end of treatments. Values are expressed as per-
centage of PI positive cells/spheroids ± SD and are mean of two or 
three independent experiments (color figure online)
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were not very strong. The Seahorse bioanalyser is an ideal 
method for the proposed AOP as it can simultaneously meas-
ure both KEs in real time. However, this becomes more cum-
bersome at longer exposures or repeated exposures, where 
supernatant lactate and cellular viability could be used to 
fill data gaps.
In summary, the study demonstrates the utility of two 
commonly used cell lines, together with OCR, ECAR, MMP, 
supernatant lactate and viability to establish critical values 
to assess chemical-induced ETC inhibition. HepG2 cells 
gave similar patterns with respect to OCR inhibition as dif-
ferentiated RPTEC/TERT1; however, glucose-free condi-
tions or 3D spheroid cultures were required to cause ETC 
inhibition-induced cytotoxicity in HepG2 cells. For studies 
investigating mitochondrial effects of compounds, we highly 
recommend the use of cell types and/or experimental condi-
tions that favour oxidative metabolism over glycolysis. This 
is of particular importance when little is known about the 
test compound and more complicated mitochondrial pertur-
bations than direct ETC inhibition are possible. Overall, the 
study presents a comprehensive example of a mitochondrial 
assessment workflow and establishes measurable key events 
of CI and CIII ETC inhibition.
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Fig. 9  Assay correlation plots. Graphs A to E show the correlation 
of the highly sensitive 30 min OCR Seahorse measurement with the 
other assays for all conditions. Each graph relates the OCR response, 
per compound and per concentration, to the one obtained with the 
correlating assay with the same treatment condition. Data include the 
mean of all replicates ± SD, slope’s r2 values are provided. Classes 
are distinguished by colour, CI inhibitors (green), CII inhibitors 
(orange) and CIII inhibitors (purple). a Basal 30 min OCR vs 24 h 
resazurin in glucose settings. b Basal 30 min OCR vs 24 h resazurin 
in galactose settings. c Basal 30  min OCR vs 24  h MMP. d Basal 
30 min OCR vs basal 30 min ECAR. e Basal 30 min OCR vs 24 h 
supernatant lactate. f This graph has the same metrics as the other 
graphs but shows the correlation of 30 min Seahorse ECAR measure-
ment with 24 h supernatant lactate measurement. Note the X-axis is 
reversed for clarity (color figure online)
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